#flozin — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #flozin, aggregated by home.social.
-
If a physician practice could get somehow get their Medicare patients on #angiotensin blockade #flozin #nsMRA and #glp1 (e.g. secondary insurance or coinsurance) why would they partner with a #VBC and share cost savings from the drugs? Just write a script & use the ...
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
HR = exp(-0.38-0.19) ~ 0.57 (43% reduction in bad kidney juju) which is very close to the estimate of 0.54 given by @brendonneuen.bsky.social by extrapolating the effect sizes of the trials available at that time. Conclusions: 1. #rstats can answer clinical questions 2. Use #GLP1RA + #flozin /
-
The nice thing about knowing #rstats, is that one can often answer some clinical questions using public data. E.g. do I expect a benefit when combining #flozin and #Glp1RA in patients living with diabetes and kidney disease? Let's use 👇from www.sciencedirect.com/science/arti... to answer the Q 1/
-
The take home point from the long term extension of the #sglt2i #flozin EMPA-KIDNEY trial is that the benefit washes VERY SOON after one stops the drug. www.nejm.org/doi/full/10.... A non-proportional hazards #stats analysis would have shown it directly, but it is also evident in the text
Long-Term Effects of Empaglifl... -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
social media discussions are a richer source of information for #Nephrology #Flozin edition than most other
https://www.kireports.org/article/S2468-0249%2823%2901295-0/fulltext
yes, there's a selection bias in who responded to the survey
h/t @kdjhaveri
-
Endothelin blockade works (eg PRECISION, and PROTECT) but does cause sodium retention. What’s the best way to proactively prevent this? In the RCTs they exclude patients with HF or high BNP, and still see weight gain. Should they be combined with a natriuretic, as @ChristosArgyrop and others have suggested?
In this small 🐀 study, adding a #Flozin to #Zibotentan did just that. Makes a lot of sense. Two good meds being synergistic. Let’s do a human trial now!
https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfad078/7143782?rss=1
-
A first for a #Flozin
No benefit with #empagliflozin in #COVID from the #RECOVERY trial
Preprint https://www.medrxiv.org/content/10.1101/2023.04.13.23288469v1.full.pdf+html
1/
-
A first for a #Flozin
No benefit with #empagliflozin in #COVID from the #RECOVERY trial
Preprint https://www.medrxiv.org/content/10.1101/2023.04.13.23288469v1.full.pdf+html
1/
-
From Ed Fu et al - but not target trial emulation, this is a propensity score matched analysis
Focusing on safety outcomes
https://journals.lww.com/cjasn/Abstract/9900/Safety_of_Sodium_Glucose_Cotransporter_2.94.aspx in #CJASN
Flozins =
More fracture
More LL amputations
More genital mycotoxins infections
But 1/
-
Another one from the giant Taiwan database
Propensity score matched etc
#Flozin vs DPP4i and subsequent #AKI - of course it’s less
But some info about why? See Figure 3 below
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801729 in @mike_johansen fav journal
Are these testable hypothesis @Bneuen from existing trials? (As cause of AKI)
-
Very cool #flozin trial in JASN
N = 14 with SIAD crossover with placebo/Empagliflozinhttps://jasn.asnjournals.org/content/early/2022/11/16/ASN.2022050623
cc @ChristosArgyrop @Kidney_boy
Do we need a larger trial, or is this enough? #hyponatremia #nephrology